A Reversal for Galectin Therapeutics Inc (NASDAQ:GALT) Is Not Near. The Stock Has Rise in Shorts

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 2.15 in 2019 Q1. Its up 1.09, from 1.06 in 2018Q4. It increased, as 3 investors sold Galectin Therapeutics, Inc. shares while 10 reduced holdings. 17 funds opened positions while 11 raised stakes. 6.26 million shares or 31.05% more from 4.77 million shares in 2018Q4 were reported.
Blackrock owns 595,501 shares for 0% of their portfolio. D E Shaw, New York-based fund reported 16,350 shares. Deutsche State Bank Ag has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Morgan Stanley invested in 0% or 58,977 shares. Financial Bank Of America De invested in 0% or 22,029 shares. The Missouri-based Cutter Communication Brokerage Inc has invested 0.08% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Neuberger Berman Ltd Liability Company owns 82,494 shares for 0% of their portfolio. Stratos Wealth Partners Ltd reported 40,950 shares. Lpl Fincl Ltd, California-based fund reported 31,877 shares. Dynamic Advisor Solutions Limited Liability Corporation invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 20,411 are owned by Citadel Advisors Limited Liability. Citigroup has 58,373 shares for 0% of their portfolio. Cwm Ltd Liability Com, Nebraska-based fund reported 2,000 shares. 14,808 were accumulated by Verition Fund Ltd Liability Corporation. Pnc Group holds 0% or 47,164 shares.

Since April 5, 2019, it had 10 insider purchases, and 0 insider sales for $20.44 million activity. LEWIS JOEL also bought $54,994 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares. CALLICUTT JACK W bought $10,075 worth of stock. $79,514 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was bought by OMENN GILBERT S. 3,033 shares valued at $12,981 were bought by ELDRED KARY on Friday, May 31. $20.03M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares were bought by Uihlein Richard E.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.23% in short interest. GALT’s total short interest was 3.80 million shares in August as published by FINRA. Its up 2.23% from 3.71 million shares, reported previously. With 408,100 shares average volume, it will take short sellers 9 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 11.04%.

The stock decreased 0.60% or $0.02 during the last trading session, reaching $3.33. About 445,559 shares traded or 28.71% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has declined 25.70% since August 15, 2018 and is downtrending. It has underperformed by 25.70% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $188.58 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 2 analysts covering Galectin Therapeutics (NASDAQ:GALT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galectin Therapeutics has $11 highest and $11 lowest target. $11’s average target is 230.33% above currents $3.33 stock price. Galectin Therapeutics had 4 analyst reports since February 23, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 7 by H.C. Wainwright. The stock has “Buy” rating by FBR Capital on Thursday, March 7.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Globenewswire.com which released: “Galectin Therapeutics Issues Statement Regarding GALTW and GALTU – GlobeNewswire” on March 23, 2017, also Seekingalpha.com with their article: “Galectin holders file to offer up to 1.7M shares – Seeking Alpha” published on August 09, 2019, Nasdaq.com published: “Health Care Sector Update for 05/10/2016: KMPH, GALT – Nasdaq” on May 10, 2016. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Seekingalpha.com and their article: “Genfit And The NASH Education Program: The Race To Inform – Seeking Alpha” published on April 05, 2019 as well as Globenewswire.com‘s news article titled: “Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering – GlobeNewswire” with publication date: May 23, 2019.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.